The Life Sciences Report: Greg, you are coming off of a pretty good year. Congratulations on that. I realize that 2012 was a good year in general for biotech. What was that about?
Greg Wade: It was about the healthy financing we saw throughout the year, which was facilitated by a couple of factors. A widespread decline in volatility globally in the marketplace was notable. Low volatility creates healthy financing environments. Risk capital was seeking an environment where growth could be generated against a backdrop of global economic uncertainty. That made healthcare an … [visit site to read more]